. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006;44(12):1472-80. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ42
(CSF)
AD
(94)
403.3 ± 160.8
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
Aβ42
(CSF)
CTRL-
Other Controls
(60)
719.2 ± 303.2
pg/mL
ELISA;
Innotest;
Innogenetics
Aβ42
(CSF)
DLB
(60)
454.8 ± 177.1
pg/mL
ELISA;
Innotest;
Innogenetics
McKeith et al., 1996
tau-p181
(CSF)
AD
(94)
84.5 ± 38.1
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
tau-p181
(CSF)
CTRL-
Other Controls
(60)
44.2 ± 16.2
pg/mL
ELISA;
Innotest;
Innogenetics
tau-p181
(CSF)
DLB
(60)
49.8 ± 22.5
pg/mL
ELISA;
Innotest;
Innogenetics
McKeith et al., 1996
tau-total
(CSF)
AD
(94)
648.8 ± 342.1
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
tau-total
(CSF)
CTRL-
Other Controls
(60)
226.6 ± 125.2
pg/mL
ELISA;
Innotest;
Innogenetics
tau-total
(CSF)
DLB
(60)
326.8 ± 241.7
pg/mL
ELISA;
Innotest;
Innogenetics
McKeith et al., 1996

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.